{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:13Z","timestamp":1789578133028,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcv.2025.105870","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:17:06Z","timestamp":1757542626000},"page":"105870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing"],"prefix":"10.1016","volume":"181","author":[{"given":"Michelle L.","family":"D'Antoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Andreatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Hindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"VanderVeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2025.105870_bib1","unstructured":"Department of Health and Human Services (DHHS), Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Last accessed: 2 April 2025."},{"key":"10.1016\/j.jcv.2025.105870_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008378","article-title":"HIV-1 variants are archived throughout infection and persist in the reservoir","volume":"16","author":"Brooks","year":"2020","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.jcv.2025.105870_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing human immunodeficiency virus (HIV) proviral DNA to assess for the presence of HIV drug resistance","author":"Wensing","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2025.105870_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The biology of the HIV-1 latent reservoir and implications for cure strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jcv.2025.105870_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40121-021-00419-5","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV aged \u226565 years: week 48 results of a phase 3b, open-label trial","volume":"10","author":"Maggiolo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jcv.2025.105870_bib6","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","author":"Maggiolo","year":"2022","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2025.105870_bib7","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2025.105870_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QAI.0000000000002731","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study","volume":"88","author":"Hagins","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2025.105870_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad146","article-title":"HIV-1 DNA testing in viremic patients identifies more drug resistance than HIV-1 RNA testing","volume":"10","author":"Curanovic","year":"2023","journal-title":"Open Forum Infect. Dis."},{"issue":"30","key":"10.1016\/j.jcv.2025.105870_bib10","first-page":"559","article-title":"Update of the drug resistance mutations in HIV-1","volume":"2022","author":"Wensing","year":"2022","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jcv.2025.105870_bib11","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkae164","article-title":"The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type","volume":"79","author":"Teyssou","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2025.105870_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiab413","article-title":"Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients","volume":"225","author":"Palich","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2025.105870_bib13","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2025.105870_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz034","article-title":"Persistence of human immunodeficiency virus-1 drug resistance mutations in proviral deoxyribonucleic acid after virologic failure of efavirenz-containing antiretroviral regimens","volume":"6","author":"De La Cruz","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jcv.2025.105870_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae212","article-title":"Sequence analysis of inducible, replication-competent virus reveals no evidence of HIV-1 evolution during suppressive antiviral therapy, indicating a lack of ongoing viral replication","volume":"11","author":"Lee","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.jcv.2025.105870_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171554","article-title":"The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy","volume":"133","author":"McMyn","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jcv.2025.105870_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2025.105870_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2025.105870_bib19","unstructured":"GlaxoSmithKline, Janssen Pharmaceuticals, CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use: US Prescribing Information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf. Last accessed: 2 April 2025."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665322500112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665322500112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T15:30:09Z","timestamp":1764257409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138665322500112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"alternative-id":["S138665322500112X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2025.105870","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2025.105870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105870"}}